CARE - Quality Improvement in Cardiovascular Secondary Prevention in Primary Care, Through Delegation of Consultations to the Nurse.

This study is currently recruiting participants.

Verified by AstraZeneca, December 2008

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00713960

Purpose

Quality Improvement in Primary Care: delegation of check-ups to nurses in general practice

Condition
Cardiovascular Disease

Study Type:	Observational
Study Design:	Prospective
Official Title:	CARE - Quality Development in Cardiovascular Disease in General Practice

Further study details as provided by AstraZeneca:

Primary Outcome Measures:

Cholesterol, HDL -cholesterol, LDL-Cholesterol, Blood pressure, Exercise, Waist-circumference, BMI, Smoking status, fasting plasma-glucose, medication taken [ Time Frame: As needed, min. baseline and after 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Number of visits pr. patients, drop-out [ Time Frame: Annually ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Estimated Enrollment:	2000
Study Start Date:	June 2008
Estimated Study Completion Date:	December 2009

Groups/Cohorts
1 Patients in secondary prevention of cardiovascular disease in primary care

Eligibility

Study Population

Primary care clinic

Criteria

Inclusion Criteria:

Patients in secondary prevention of cardiopathy (ischaemic heart disease, claudication intermittence, thrombotic apoplexy cerebri, diabetes) who are not followed in an outpatient department.

Exclusion Criteria:

Patients who suffer from diabetic nephropathy will be excluded
According to the general practitioners appraisal, patients who suffer from severe co morbidity can be excluded as well.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00713960

Contacts

Contact: AstraZeneca Clinical Study Information

+4543666264

Sponsors and Collaborators

AstraZeneca

Investigators

Study Chair:	Henrik Ommen, MD	Lægerne i Løgumkloster I/S, Denmark
Study Chair:	Dorte Knudsen	Lægerne Sønderåparken, Denmark

More Information

Responsible Party:	AstraZeneca Pharmaceuticals ( Inge Vestbo, Medical Director )
Study ID Numbers:	NIS-CDK-DUM-2008/1
Study First Received:	July 10, 2008
Last Updated:	December 15, 2008
ClinicalTrials.gov Identifier:	NCT00713960
Health Authority:	Denmark: Danish Dataprotection Agency

Keywords provided by AstraZeneca:

Quality development project
primary care nurses
cardiovascular disease
secondary prevention
follow-up

Study placed in the following topic categories:

Neoplasm Metastasis

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 14, 2009